Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2016-08-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14712598.2016.1221920PMID 27533882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

  2018cited by this paper
• The European Hematology Association (EHA)

  2018cited by this paper
• Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cited by this paper
• Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma

  2016cited by this paper
• Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)

  2016cited by this paper
• Summary of product characteristics

  2016cited by this paper
• Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

  2016influential reference
• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

  2016influential reference
• Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

  2015cited by this paper
• Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

  2015influential reference
• Management of relapsed multiple myeloma after autologous stem cell transplant.

  2015influential reference
• Immune therapy in multiple myeloma.

  2015cited by this paper
• Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

  2015cited by this paper
• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

  2015influential reference
• Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up

  2015influential reference
• Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma

  2015cited by this paper
• A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).

  2015cited by this paper
• Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)

  2015cited by this paper
• An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

  2015cited by this paper
• Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

  2015influential reference
• The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

  2014cited by this paper
• Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells

  2014cited by this paper
• Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma

  2014cited by this paper
• Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

  2014cited by this paper
• International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

  2014cited by this paper
• Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

  2013influential reference
• Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma

  2013influential reference
• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2013cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

  2012cited by this paper
• Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

  2012cited by this paper
• Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

  2012influential reference
• A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

  2012influential reference
• Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

  2012cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis

  2011cited by this paper
• Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

  2011cited by this paper
• Cancer immunology.

  2011cited by this paper
• Interference of monoclonal antibody therapies with serum protein electrophoresis tests.

  2010cited by this paper
• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Recent advances in the management of multiple myeloma.

  2010cited by this paper
• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

  2010cited by this paper
• Future of cancer incidence in the United States: burdens upon an aging, changing nation.

  2009cited by this paper
• CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

  2008influential reference
• Cancer Immunology

  2008cited by this paper
• Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

  2008influential reference
• Improved survival in multiple myeloma and the impact of novel therapies.

  2008cited by this paper
• Cancer statistics

  1989cited by this paper

• Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma

  2024cites this paper
• Cardiac Complications of Multiple Myeloma Treatments.

  2024cites this paper
• CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy

  2024cites this paper
• Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022

  2024cites this paper
• Current status of bispecific antibodies and CAR-T therapies in multiple myeloma.

  2024cites this paper
• CAR T cell therapies for patients with multiple myeloma

  2020cites this paper
• A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

  2020cites this paper
• Signaling Lymphocytic Activation Molecule Family-7 Alleviates Corneal Inflammation by Promoting M2 Polarization.

  2020cites this paper
• Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide

  2020cites this paper
• Therapeutic targets of FDA-approved immunotherapies in oncology

  2018cites this paper
• Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma

  2018cites this paper
• Cancer immunotherapy: Breakthrough or “deja vu, all over again”?

  2017cites this paper
• A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

  2017influential citation
• Mechanisms of Action and Clinical Development of Elotuzumab

  2017cites this paper